The Eye Association feels that it’s important to always be on the cutting edge of new technology. Our physicians and staff routinely participate in national educational meetings and workshops, either learning or teaching others about the latest treatment options for our patients. Because of this, The Eye Associates has been chosen to participate in many clinical studies in order to advance eye-related research and bring the latest treatments to patients.
The Eye Associates conducts various clinical research studies on Glaucoma, Cataracts, Dry Eyes, Retinal, IOLs, Uveitis, Blepharitis, Contact Lenses, Surgical Drugs and more. To find out if we are recruiting participants for a condition that you have, please contact clinical research studies at (941) 220-5987.
The following are some of the studies that we are currently recruiting for:
Objective:
Approximately 14 week study to evaluate the safety and efficacy of 5% tavilermide and 1% tavilermide ophthalmic solutions compared with placebo ophthalmic solution in treating the signs and symptoms of dry eye.
Eligibility:
Patients must be 18 years or older. History of at least 6 months of Dry Eye Syndrome symptom complaints.
History of artificial tear use to manage dry eye syndrome symptoms.
Compensation:
Study patients receive free office visits; eyecare; and travel and time compensation during the study.
Objective:
3-year study to evaluate the efficacy of a medical implant containing an approved drug called Travaoprost that reduces high eye pressure in patients with ocular hypertension open-angle glaucoma.
Eligibility:
Patients must be 18 years or older. Diagnosed with ocular hypertension or open-angle glaucoma. Currently taking 0-2 medications for ocular hypertension or open-angle glaucoma.
Compensation:
Study patients receive free office visits; eyecare; and travel and time compensation during the study.
Objective:
The purpose of this clinical study is to evaluate the efficacy and safety of two different levels of conbercept injections compared to the approved active control, aflibercept injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.
Eligibility:
Patients must be 50 years or older and have received no prior treatment for wet AMD.
Compensation:
Study patients receive free office visits; eyecare; and travel and time compensation during the study.
